热门资讯> 正文

Akeso报告财年业绩

2025-04-01 01:26

stem(STEM) 0
Harbor AlphaEdge Small Cap Earners ETF(EBIT) 0
Summit Therapeutic(SMMT) 0

Akeso press release (OTCPK:AKESF): FY On the commercial front, Akeso's adjustments in drug pricing and optimization of its commercial systems led to new drug sales revenue surpassing RMB 2 billion in 2024, a 25% year-on-year increase.
The company continues to reduce operating losses, with an EBITDA loss of 225 million RMB in 2024.
In 2024, Akeso Biopharma achieved commercial sales of RMB 2 billion, representing a 25% year-over-year growth.

More on Akeso

Summit Therapeutics to test lead cancer drug with Pfizer ADCs
Historical earnings data for Akeso
Financial information for Akeso

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。